3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
48
Lymphoma
34
Lymphoma, Large B-Cell, Diffuse
32
Lymphoma, Non-Hodgkin
23
Osteosarcoma
21
Hodgkin Disease
17
Testicular Neoplasms
16
Burkitt Lymphoma
13
Testicular Germ Cell Tumor
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Ovarian Neoplasms
12
Teratoma
9
Neuroectodermal Tumors, Primitive, Peripheral
9
Lymphoma, Large-Cell, Immunoblastic
9
Lymphoma, Follicular
9
Neuroblastoma
8
Lymphoma, Large-Cell, Anaplastic
8
Central Nervous System Neoplasms
8
Recurrence
7
Lymphoma, Mantle-Cell
7
Lymphoma, B-Cell
7
Leukemia
7
Endodermal Sinus Tumor
7
Seminoma
6
Rhabdomyosarcoma
6
Lymphoma, B-Cell, Marginal Zone
6
Breast Neoplasms
6
Small Cell Lung Carcinoma
5
Neoplasms, Germ Cell and Embryonal
5
Neoplasms
5
Interventions
Diathermy
20
Radiotherapy
11
Fluorouracil
4
Drug Therapy
4
Cisplatin
4
Radiation
3
Immune Checkpoint Inhibitors
3
Brachytherapy
3
tislelizumab
2
Surgical Procedures, Operative
2
Solutions
2
Immunotherapy
2
Hyperthermia, Induced
2
Hydrogen Peroxide
2
Conization
2
Capecitabine
2
spartalizumab
1
anlotinib
1
Temozolomide
1
Saline Solution
1
Radiation Dose Hypofractionation
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Oxaliplatin
1
Mitomycin
1
Ifosfamide
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gemcitabine
1
Folfox protocol
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hyperthermia
×
Ifosfamide
×
Clear all
NCT06835049
2025-12-30
TNT-HYPE
Swiss Cancer Institute
Phase 2
Recruiting
24 enrolled